MTOR and posterior cortical atrophy: Although mTOR inhibitors have been ineffective against PCa in clinical trials so far due to high toxicity and the activation of feedback mechanisms [153], many other amino acid–mTORC1 signalling pathway components may still be suitable therapeutic targets for anti-PCa treatment.